Viatris Product and Service, Other — Other revenues decreased by 41.1% to $7.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.2%, from $11.10M to $7.30M. Over 2 years (FY 2021 to FY 2023), Product and Service, Other — Other revenues shows a downward trend with a -27.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful monetization of secondary assets or expanded service offerings, while a decrease may indicate a decline in non-core business activities or a strategic shift toward primary product focus.
This metric represents revenue streams generated by a business segment that fall outside of its primary core product or...
Similar to 'Other Revenue' or 'Ancillary Income' reported by other large-cap pharmaceutical and generic drug manufacturers, often representing a small but stable percentage of total top-line results.
vtrs_segment_product_and_service_other_other_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.10M | $16.10M | $10.30M | $13.50M | $11.40M | $10.80M | $8.90M | $10.00M | $9.10M | $8.00M | $11.40M | $9.90M | $10.70M | $13.20M | $11.10M | $13.10M | $12.40M | $7.30M |
| QoQ Change | — | +0.0% | -36.0% | +31.1% | -15.6% | -5.3% | -17.6% | +12.4% | -9.0% | -12.1% | +42.5% | -13.2% | +8.1% | +23.4% | -15.9% | +18.0% | -5.3% | -41.1% |
| YoY Change | — | — | — | — | -29.2% | -32.9% | -13.6% | -25.9% | -20.2% | -25.9% | +28.1% | -1.0% | +17.6% | +65.0% | +12.1% | +22.4% | -6.1% | -34.2% |